NASDAQ$CRVO
Diffusion Pharmaceuticals Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Diffusion Pharmaceuticals reported financial results for the first quarter of 2022 and provided a business update.
Diffusion Pharmaceuticals reported its Q1 2022 financial results, highlighting the completion of dosing in the Altitude Trial with topline data expected in June 2022, continued enrollment in the TSC ILD-DLCO Trial, expansion of the Scientific Advisory Board, and a solid cash position of $32.6 million. The company also regained compliance with the Nasdaq bid price rule.
- Completed dosing in Altitude Trial with topline data expected in June 2022.
- Continued enrollment in TSC ILD-DLCO Trial, anticipating completion of dosing in the second half of 2022.
- Expanded Scientific Advisory Board with the addition of five prominent radiation and medical oncologists.
- Maintained a solid cash position with $32.6 million in cash, cash equivalents, and marketable securities as of March 31, 2022.
Headline financials
Revenue & EPS history
CervoMed · Revenue · Quarterly
$0
Forward guidance
Diffusion Pharmaceuticals anticipates topline data readout from the Altitude Trial in June and completion of patient dosing in the ILD-DLCO trial later in 2022. The company is also focused on launching its Hypoxic Solid Tumor Program.
Tailwinds
- Topline data readout from the Altitude Trial expected in June.
- Completion of patient dosing in ILD-DLCO trial anticipated later this year.
- Focus on launching Hypoxic Solid Tumor Program.
- Strong cash position to fund operations through 2023.
- Experienced development team and new SAB members to support the program.
Headwinds
- Uncertainties related to the design, initiation, enrollment, execution, and completion of studies evaluating TSC.
- Risks associated with regulatory approval of TSC for solid tumors or any other indication.
- Potential impact of supply chain and supplier issues on the clinical development program.
- Company's ability to protect and expand its intellectual property portfolio.
- General economic, political, business, industry, and market conditions.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
+0.4%
Avg return
Earnings day
+177.7%
Avg return
5 days after
-10.0%
Avg return
30 days after
31%
20 / 65 earnings
Positive
+39.3%
Q1 2020
Best reaction
-27.6%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -8.5% | — | — | |
| Q4 2025 | +5.1% | -6.7% | -7.4% | |
| Q3 2025 | -0.3% | +11.0% | +25.3% | |
| Q2 2025 | +5.5% | +3.2% | +12.5% | |
| Q1 2025 | +0.0% | -4.1% | -17.3% | |
| Q4 2024 | +3.2% | +57.9% | +8.3% | |
| Q3 2024 | -7.6% | -11.3% | -84.1% | |
| Q2 2024 | +33.0% | +61.9% | +39.3% | |
| Q1 2024 | -1.4% | -20.1% | -23.0% | |
| Q4 2023 | -4.9% | -12.0% | +3.7% | |
| Q3 2023 | -2.6% | +0.2% | -10.6% | |
| Q2 2023 | -1.1% | +9.5% | +10.4% | |
| Q1 2023 | -5.4% | -1.7% | -11.3% | |
| Q4 2022 | -8.7% | -12.7% | -27.1% | |
| Q3 2022 | +21.4% | +22.0% | +28.6% | |
| Q2 2022 | -2.0% | -1.4% | -7.1% | |
| Q1 2022 | +18.6% | +25.5% | +25.5% | |
| Q4 2021 | -3.7% | +0.0% | -43.0% | |
| Q3 2021 | -6.7% | -4.4% | -15.6% | |
| Q2 2021 | -7.0% | -14.0% | -3.5% | |
| Q1 2021 | +0.0% | +6832.2% | +13.2% | |
| Q4 2020 | +4.9% | +4.9% | -99.1% | |
| Q3 2020 | -10.1% | -20.3% | -6.3% | |
| Q2 2020 | -0.9% | -1.8% | -22.7% | |
| Q1 2020 | +39.3% | +121.3% | +77.0% | |
| Q4 2019 | -8.8% | -17.6% | +17.6% | |
| Q3 2019 | -27.6% | -69.7% | -25.0% | |
| Q2 2019 | -0.9% | -3.7% | -10.6% | |
| Q1 2019 | -4.9% | -3.8% | -29.6% | |
| Q4 2018 | +3.8% | -4.3% | -33.6% | |
| Q3 2018 | +0.0% | -12.1% | -41.8% | |
| Q2 2018 | +2.8% | +13.9% | +11.1% | |
| Q4 2017 | -3.6% | -11.3% | -1.9% | |
| Q1 2018 | -3.6% | +1.8% | +1.8% | |
| Q3 2017 | -3.6% | -1.5% | +3.6% | |
| Q2 2017 | -7.7% | +0.0% | +12.5% | |
| Q4 2016 | -0.6% | +3.1% | -15.8% | |
| Q1 2017 | -0.6% | +3.1% | -15.8% | |
| Q3 2016 | -3.8% | -4.8% | -40.0% | |
| Q2 2016 | +0.0% | +0.0% | -90.0% | |
| Q1 2016 | +11.1% | — | — | |
| Q4 2015 | -6.4% | — | — | |
| Q3 2015 | -9.1% | — | — | |
| Q2 2015 | +1.2% | — | — | |
| Q1 2015 | -2.0% | — | — | |
| Q4 2014 | -7.1% | — | — | |
| Q3 2014 | -1.1% | — | — | |
| Q2 2014 | +4.5% | — | — | |
| Q1 2014 | -3.2% | — | — | |
| Q4 2013 | +0.0% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | +0.0% | — | — | |
| Q4 2012 | +18.8% | — | — | |
| Q3 2012 | +4.8% | — | — | |
| Q2 2012 | -2.6% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +8.0% | — | — | |
| Q3 2011 | -11.5% | — | — | |
| Q2 2011 | +7.1% | — | — | |
| Q1 2011 | +5.5% | — | — | |
| Q4 2010 | +1.6% | — | — | |
| Q3 2010 | +19.0% | — | — | |
| Q2 2010 | -12.0% | — | — | |
| Q1 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro